77 related articles for article (PubMed ID: 23466569)
1. Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from Asia.
Sharma DN; Rath GK; Julka PK; Gandhi AK; Jagadesan P; Kumar S
Int J Gynecol Cancer; 2013 May; 23(4):705-9. PubMed ID: 23466569
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
Goncalves A; Fabbro M; Lhommé C; Gladieff L; Extra JM; Floquet A; Chaigneau L; Carrasco AT; Viens P
Gynecol Oncol; 2008 Jan; 108(1):42-6. PubMed ID: 17980406
[TBL] [Abstract][Full Text] [Related]
3. A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.
Dawson NA; Guo C; Zak R; Dorsey B; Smoot J; Wong J; Hussain A
Clin Cancer Res; 2004 Dec; 10(23):7812-9. PubMed ID: 15585612
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
Choi MK; Hong JY; Chang WJ; Kim MJ; Kim SM; Jung HA; Do IG; Choi YL; Sun JM; Ahn JS; Park K; Ahn MJ
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1229-36. PubMed ID: 25903122
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Cohen EE; Kane MA; List MA; Brockstein BE; Mehrotra B; Huo D; Mauer AM; Pierce C; Dekker A; Vokes EE
Clin Cancer Res; 2005 Dec; 11(23):8418-24. PubMed ID: 16322304
[TBL] [Abstract][Full Text] [Related]
6. Preoperative hyperfractionated chemoradiation for locally recurrent rectal cancer in patients previously irradiated to the pelvis: A multicentric phase II study.
Valentini V; Morganti AG; Gambacorta MA; Mohiuddin M; Doglietto GB; Coco C; De Paoli A; Rossi C; Di Russo A; Valvo F; Bolzicco G; Dalla Palma M;
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1129-39. PubMed ID: 16414206
[TBL] [Abstract][Full Text] [Related]
7. Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Dudek AZ; Kmak KL; Koopmeiners J; Keshtgarpour M
Lung Cancer; 2006 Jan; 51(1):89-96. PubMed ID: 16290256
[TBL] [Abstract][Full Text] [Related]
8. Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Franceschi E; Cavallo G; Lonardi S; Magrini E; Tosoni A; Grosso D; Scopece L; Blatt V; Urbini B; Pession A; Tallini G; Crinò L; Brandes AA
Br J Cancer; 2007 Apr; 96(7):1047-51. PubMed ID: 17353924
[TBL] [Abstract][Full Text] [Related]
9. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
[TBL] [Abstract][Full Text] [Related]
10. A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction.
Adelstein DJ; Rodriguez CP; Rybicki LA; Ives DI; Rice TW
Invest New Drugs; 2012 Aug; 30(4):1684-9. PubMed ID: 21863238
[TBL] [Abstract][Full Text] [Related]
11. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
[TBL] [Abstract][Full Text] [Related]
12. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
[TBL] [Abstract][Full Text] [Related]
13. Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.
Yoshida K; Yatabe Y; Park JY; Shimizu J; Horio Y; Matsuo K; Kosaka T; Mitsudomi T; Hida T
J Thorac Oncol; 2007 Jan; 2(1):22-8. PubMed ID: 17410005
[TBL] [Abstract][Full Text] [Related]
14. Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Argiris A; Mittal N
Lung Cancer; 2004 Mar; 43(3):317-22. PubMed ID: 15165090
[TBL] [Abstract][Full Text] [Related]
15. Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
Koizumi T; Agatsuma T; Ikegami K; Suzuki T; Kobayashi T; Kanda S; Yoshikawa S; Kubo K; Shiina T; Takasuna K; Matsuo A; Hayasaka M; Morikawa M; Ameshima S
Clin Lung Cancer; 2012 Nov; 13(6):458-63. PubMed ID: 22402083
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of EGFR inhibitor gefitinib in recurrent or metastatic cervical cancer: a preliminary report.
Krishna A; Sathya M; Mukesh S; Athiyamaan MS; Banerjee S; Sunny J; Srinivas C; Lobo D; Makkapatti BS; Jawahar V
Med Oncol; 2023 Jun; 40(7):203. PubMed ID: 37310466
[TBL] [Abstract][Full Text] [Related]
17. The Efficacy And Safety Of Apatinib Treatment For Patients With Metastatic Or Recurrent Cervical Cancer: A Retrospective Study.
Yu J; Xu Z; Li A; Zhang J; Wang Y; Zhao H; Zhu H
Drug Des Devel Ther; 2019; 13():3419-3424. PubMed ID: 31576114
[TBL] [Abstract][Full Text] [Related]
18. A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.
Ma B; Hui EP; King A; To KF; Mo F; Leung SF; Kam M; Lo YM; Zee B; Mok T; Ahuja A; Chan AT
Cancer Chemother Pharmacol; 2008 Jun; 62(1):59-64. PubMed ID: 17762933
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
Liam CK; Pang YK; Leow CH
Respirology; 2006 May; 11(3):287-91. PubMed ID: 16635086
[TBL] [Abstract][Full Text] [Related]
20. Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K; Ueoka H; Tabata M; Fujiwara K; Kozuki T; Okada T; Hisamoto A; Tanimoto M
Lung Cancer; 2004 Nov; 46(2):255-61. PubMed ID: 15474674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
